Not Yet RecruitingNCT07798375
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
PHASE2 · 244 planned enrolment
- Countries listed
- 0
- Registry update
- September 10, 2026
immortal.lifeTrial registrations containing the exact intervention label Aflibercept (Eylea).
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE2 · 244 planned enrolment
PHASE4 · 48 planned enrolment